title: Nocturnal akathisia in Parkinson's disease: treatment with clozapine.
abstract: We present the results obtained using low doses of clozapine (mean dose 26.4 mg at bedtime) in the treatment of nocturnal akathisia in nine patients with Parkinson's disease for a mean period of 12.5 months. The results were excellent in all the patients. Furthermore, three patients experienced a remarkable improvement in rest tremor and in five patients the confusional state that accompanied the akathisia also disappeared. No serious side-effects were observed. We believe that clozapine is a very useful drug for the relief of nocturnal akathisia in parkinsonian subjects.
authors: Section of Neurology, Hospital Nuestra Senora de Arantzazu, San Sebastián, Spain.
authors: G
authors: G
authors: Linazasoro
authors: J F
authors: JF
authors: Martí Massó
authors: J A
authors: JA
authors: Suárez
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001545:Benserazide / Q000008:administration & dosage / Q000009:adverse effects; D002230:Carbidopa / Q000008:administration & dosage / Q000009:adverse effects; D002940:Circadian Rhythm / Q000187:drug effects; D003024:Clozapine / Q000009:adverse effects / Q000627:therapeutic use*; D003221:Confusion / Q000188:drug therapy; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009460:Neurologic Examination / Q000187:drug effects; D010300:Parkinson Disease / Q000188:drug therapy*; D011595:Psychomotor Agitation / Q000188:drug therapy*; D012893:Sleep Wake Disorders / Q000188:drug therapy*
chemical_list: D001545:Benserazide; D003024:Clozapine; D002230:Carbidopa